Navigation Links
Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
Date:5/14/2009

FREMONT, Calif., May 14 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "siRNA Therapeutics for Prevention of Ocular and Inner Ear Sensory Cells Death," at the DxRx Summit: Nucleic Acid Diagnostics & Therapeutics. The event was held May 12-13, 2009 in Boston, MA.

Dr. Feinstein presented data demonstrating that synthetic, chemically-modified 19-bp siRNAs, including PF 04523655 currently being studied by partners Pfizer and Quark in patients with diabetic macular edema (DME) and age-related macular degeneration (AMD), enter cells in the retina of the eye and exert their therapeutic effects while avoiding non-specific activation of the toll-like receptor 3 (TLR3) - the effect reported for other synthetic siRNAs. Similar data for QPI-1007, Quark's proprietary siRNA composition, were also reported. QPI-1007 was demonstrated to confer effective ocular neuroprotection and is currently in late-stage IND-enabling studies.

In addition to studies in the eye, Dr. Feinstein also reported results demonstrating effective delivery of synthetic siRNAs to the inner ear, which resulted in protection of hearing epithelium from ototoxic and noise-induced damage. These studies were performed in collaboration with Prof. Jayakrishna Ambati, University of Kentucky College of Medicine, Lexington, KY; Prof. Ann Logan, University of Birmingham, UK; Prof. Adriana Di Polo, University of Montreal; and Prof. Richard Salvi, SUNY University at Buffalo.

Daniel Zurr, Ph.D., President and Chief Executive Officer, said, "Results from the studies presented at DxRx demonstrate our successful track record in discovering and advancing industry-leading siRNA product candidates. Our strong position in the RNAi landscape has been validated by our ability to secure co-development agreements with major pharmaceutical partners, including Pfizer, to advance our siRNA product candidates further towards commercialization."

Dr. Feinstein added, "Our synthetic, chemically modified siRNA product candidates have been designed to elicit pharmacologic effects through target gene-knock down while avoiding potentially harmful off-target effects reported for other synthetic siRNAs. These results support our capabilities to discover and develop siRNA product candidates with greater specificity and reduced side effects."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-04523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-04523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from Alnylam Pharmaceuticals.

QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally. The Company expects to utilize the structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com.

    Quark Pharmaceuticals, Inc.       The Ruth Group (investors / media)
    Juliana Friedmann                 Sara Ephraim Pellegrino / Janine McCargo
    +972 89 30 5111                   (646) 536-7002 / 7033
    jfriedman@quarkpharma.com         spellegrino@theruthgroup.com
                                      jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
2. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
5. MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
7. Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
8. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
9. Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
10. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
11. Vion Pharmaceuticals Reports 2009 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 2016 , ... There are many ways to cook a hot dog, but ... Americans prefer their dogs straight off the grill. Of the 90 percent of Americans ... to cook a hot dog, far outpacing other cooking methods such as steaming (12 ...
(Date:5/26/2016)... Oakland, California (PRWEB) , ... May 26, 2016 ... ... liabilities associated with discovery of thousands of defective respirators, according to court documents ... in the case of William and Becky Tyler v. American Optical Corporation, Case ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... Washington, D.C. (PRWEB) , ... May 26, 2016 , ... ... the men and women who lost their lives in military battle for the country. ... discount cards in 2015 to provide more programs that empower independence for disabled military ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... that has a significant negative impact on long-term patient survival, reports a team ... results, published online this week in the Journal of Thoracic and Cardiovascular Surgery, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... IRVINE, Calif. , May 25, 2016 /PRNewswire/ ... of testing for their new reference materials that ... workflows from sample collection to analyses. The rapid ... the demand for researchers to have standard methods ... data being generated. Biases inherently exist at every ...
(Date:5/25/2016)... CHESTERFIELD, Va. , May 25, 2016 /PRNewswire/ ... next-generation sequencing test for wounds and infections. This ... ALL parasites, and select viruses. The test requires ... area. David G. Bostwick ... molecular testing to facilitate wound healing: "We are ...
Breaking Medicine Technology: